Is Capricor Therapeutics Incorporated (NASDAQ:CAPR) a Buy? The Stock Reported more Sellers

September 17, 2017 - By test

 Is Capricor Therapeutics Incorporated (NASDAQ:CAPR) a Buy? The Stock Reported more Sellers

Investors sentiment decreased to 1 in 2016 Q4. Its down 0.33, from 1.33 in 2016Q3. It is negative, as 4 investors sold Capricor Therapeutics Inc shares while 2 reduced holdings. 2 funds opened positions while 4 raised stakes. 764,994 shares or 9.01% less from 840,701 shares in 2016Q3 were reported.
Geode Cap Limited Liability Com accumulated 43,929 shares or 0% of the stock. Susquehanna Group Incorporated Llp accumulated 14,319 shares or 0% of the stock. Blackrock Invest Mgmt Limited Liability stated it has 0% of its portfolio in Capricor Therapeutics Inc (NASDAQ:CAPR). Blackrock Fund Advsrs stated it has 16,598 shares or 0% of all its holdings. Moreover, Morgan Stanley has 0% invested in Capricor Therapeutics Inc (NASDAQ:CAPR) for 39,000 shares. Perceptive Ltd Liability Company owns 4,000 shares. Blackrock Advsr Ltd Llc accumulated 1,665 shares or 0% of the stock. Goldman Sachs Group, New York-based fund reported 75,561 shares. Cordasco Ntwk holds 3,100 shares. Sabby Mgmt Ltd Limited Liability Company reported 0.06% stake. 50,790 were accumulated by Vanguard Incorporated. Brown Advisory reported 0% in Capricor Therapeutics Inc (NASDAQ:CAPR). Bancorporation Of America Corp De invested in 0% or 3,000 shares. Financial Architects Inc reported 0% of its portfolio in Capricor Therapeutics Inc (NASDAQ:CAPR). Granite Point Capital Mngmt Ltd Partnership accumulated 67,500 shares.

Since May 9, 2017, it had 3 insider purchases, and 0 selling transactions for $3.66 million activity. 25,000 Capricor Therapeutics Inc (NASDAQ:CAPR) shares with value of $77,500 were bought by Musket David B. CEDARS SINAI MEDICAL CENTER had bought 1.15 million shares worth $3.55M. 10,000 Capricor Therapeutics Inc (NASDAQ:CAPR) shares with value of $31,000 were bought by Manzo Louis.

The stock of Capricor Therapeutics Incorporated (NASDAQ:CAPR) registered an increase of 16.72% in short interest. CAPR’s total short interest was 916,400 shares in September as published by FINRA. Its up 16.72% from 785,100 shares, reported previously. With 175,700 shares average volume, it will take short sellers 5 days to cover their CAPR’s short positions. The short interest to Capricor Therapeutics Incorporated’s float is 8.88%.

The stock increased 3.09% or $0.03 on September 15, reaching $1. About 1.08M shares traded or 265.46% up from the average. Capricor Therapeutics Inc (NASDAQ:CAPR) has declined 72.31% since September 17, 2016 and is downtrending. It has underperformed by 89.01% the S&P500.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology firm focused on the discovery, development and commercialization of therapeutics. The company has market cap of $23.50 million. The Firm focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. It currently has negative earnings. The Company’s product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction , while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure.

Capricor Therapeutics Inc (NASDAQ:CAPR) Ratings Coverage

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 4 analyst reports since June 15, 2016 according to SRatingsIntel. H.C. Wainwright reinitiated it with “Buy” rating and $13 target in Wednesday, July 6 report. The company was maintained on Friday, September 15 by H.C. Wainwright. The rating was initiated by Roth Capital with “Buy” on Wednesday, June 15. The firm has “Buy” rating by H.C. Wainwright given on Monday, July 10.

More notable recent Capricor Therapeutics Inc (NASDAQ:CAPR) news were published by: Prnewswire.com which released: “Capricor Therapeutics Reports First Quarter 2017 Financial Results and …” on May 15, 2017, also Prnewswire.com with their article: “Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for …” published on July 18, 2017, Thestreet.com published: “Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results” on April 25, 2017. More interesting news about Capricor Therapeutics Inc (NASDAQ:CAPR) were released by: Prnewswire.com and their article: “Capricor Therapeutics Announces Plans to Expand Clinical Development Program …” published on November 10, 2016 as well as Prnewswire.com‘s news article titled: “Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial …” with publication date: March 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.